Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-21

It's interesting to see what other ASX listed companies in the med tech field are doing in the US. I follow 4D Medical that has great tech and Sam Hupert from Pro Medicus is on the advisory board. The market cap is $197M so clearly investors like their offer of the non-invasive, quantitative analysis of lung function. However you need to have the stomach to handle the $1.3M revenue and $10M negative cash flow in the latest 4C,or the $3M revenue and $31M negative cash flow for the year. With M7T at $156M market cap and with an EV of $130M we know there is no cap raising around the corner. Cash flow positive with hopefully more signings in the 2nd half along with the VHA program - curiously 4DX has a role as well in this program. What's my point - they will definitely be a time to invest in 4DX but it's not now. At 197M market cap with money flying out the door (4DX) I can sleep at night as a M7T investor.